Have a personal or library account? Click to login
A comparison of the monocyte monolayer assay with 51chromium red cell recovery for determining the clinical significance of red cell alloantibodies Cover

A comparison of the monocyte monolayer assay with 51chromium red cell recovery for determining the clinical significance of red cell alloantibodies

By: R.J. Davey,  S.S Esty,  J.F. Chin and  D. Mallory  
Paid access
|Nov 2020

Abstract

The 51chromium (51Cr) red cell recovery study is a reliable measure of transfusion compatibility. However, the monocyte monolayer assay (MMA) does not require the use of radioactive isotopes or the injection of incompatible RBCs. In this study, 51Cr recoveries were performed on 12 patients with well-defined antibodies, and the results compared to the MMA procedure. The MMA method was interpreted by counting the percentage of monocytes with associated RBCs (>3% = positive). The MMA correlated with the 51Cr recovery in 11 of 12 subjects. One anti-K1 that caused moderately accelerated red cell destruction (60% recovery at 24 hours) had a negative MMA. Four control subjects with no atypical antibodies had normal autologous RBC 51Cr recoveries and were negative by the MMA technique. The MMA test can be a reliable predictor of in vivo antibody behavior and an acceptable alternative to 51Cr recovery studies. Immunohematology 1994;10:90–94.

DOI: https://doi.org/10.21307/immunohematology-2019-929 | Journal eISSN: 1930-3955 | Journal ISSN: 0894-203X
Language: English
Page range: 90 - 94
Published on: Nov 30, 2020
Published by: American National Red Cross
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year

© 2020 R.J. Davey, S.S Esty, J.F. Chin, D. Mallory, published by American National Red Cross
This work is licensed under the Creative Commons License.